glofitamab,Obinutuzumab 
roche
['lymsm', 'import', 'glofitamab', 'shine', 'biomarker', 'lymphoma', 'pdl']
congress #asco22 | kerry j savage discusses the last 3 trials presented. she highlights response durability as important in the glofitamab trial. in pd-1/pdl inhibitors biomarkers of response are the key goal. shine supports br + ibr as option for ndmcl #lymphoma #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm